GlassScriptPhysician profile
William M Morris
NPI 1538127923
$11,525.60
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,633 · 2020: $2,427 · 2021: $1,304 · 2022: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,934.02 | 2019-2022 | |
| Boston Scientific Corporation | $2,782.80 | 2019-2021 | |
| Edwards Lifesciences Corporation | $2,464.80 | 2019-2022 | |
| Abiomed | $868.23 | 2019-2022 | |
| Inari Medical, INC. | $132.88 | 2019-2021 | |
| Medtronic Vascular, INC. | $76.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $56.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $37.34 | 2021 | |
| Medtronic, INC. | $35.34 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $34.97 | 2021 | |
| Penumbra, INC. | $25.90 | 2020-2021 | |
| Cardiovascular Systems INC. | $20.71 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.73 | 2021 | |
| Terumo Medical Corporation | $13.76 | 2022 | |
| Angiodynamics, INC. | $13.57 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $13.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.